v3.26.1
LICENSING AGREEMENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2022
Dec. 28, 2020
May 17, 2017
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Aug. 31, 2023
Sep. 30, 2021
Jan. 31, 2021
Dec. 31, 2020
Dec. 12, 2020
Feb. 02, 2016
Number of shares                           43,112
Additional CMH payment       $ 50,000   $ 50,000                
Obligation due under agreement through the issuance of common stocks           300,000                
Payment for clinical trial           200,000                
Common stock value       6,491   6,491   $ 3,144           $ 100,000
Patents gross       300,000   $ 300,000                
Total obligation under the agreement                   $ 300,000   $ 100,000 $ 300,000  
Initial payment of obligation                   $ 40,000   $ 50,000 $ 50,000  
Balance of obligation, description           The remaining portion of the $300,000 obligation was paid in cash in 2020.                
Remaining portion of obligation                 $ 100,000          
Amortization       $ 22,918 $ 30,742 $ 51,773 $ 61,319              
Amortization expenses           $ 17,971 22,970              
Common stock shares       6,497,008   6,497,008   3,701,668            
Description of payment on conversion basis     Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date                      
Description for the consecutive trading days     In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles                      
Payments upon completion of the IRB clinical trial     $ 200,000                      
Payments in the event of commercialization of technology           $ 300,000                
Licensing Agreements [Member]                            
Amortization           0                
Payments upon dosing of the first patient in Phase 3 clinical trial           100,000                
Jadi Cell [Member]                            
Pyment for license fees $ 250,000 $ 250,000                        
Common stock shares 18,018                          
StemSpine LLC [Member]                            
Amortization           5,503 5,267              
Carrying value of patent       $ 8,636   $ 8,636                
Expiration period of finite-lived intangible assets           May 19, 2027                
Amortization           $ 8,636                
Option Warrant [Member]                            
Amortization           12,390 12,479              
Carrying value of patent       112,534   112,534                
Amortization           25,000                
Initial payment     100,000                      
Payments upon dosing of the first patient in Phase 3 clinical trial     400,000     100,000                
Payments upon dosing of the first patient first patient in a Phase 1-2 clinical trial     $ 200,000                      
ImmCelz Patent [Member]                            
Common stock, shares                   8,466 8,929   667  
Patents gross       200,000   $ 200,000                
Discount rate           25.00%                
Amortization           $ 9,912 9,912              
Interest rate           5.00%                
Carrying value of patent       161,746   $ 161,746                
Exercise price           $ 0.0037                
Amortization           $ 20,000                
EDI Patent [Member]                            
Amortization           1,044 4,986              
Carrying value of patent       0   0                
IND [Member]                            
Patents gross       100,000   100,000                
Amortization           4,981 $ 4,981              
Carrying value of patent       72,541   72,541                
Amortization           10,000                
Patents [Member]                            
Carrying value of patent       $ 0   0                
Amortization           $ 300,000